Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

Trial Profile

Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Sun Pharma Advanced Research Company
  • Most Recent Events

    • 20 Oct 2016 Status changed from recruiting to completed.
    • 08 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.
    • 08 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top